Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raludotatug Deruxtecan in Advanced Gastrointestinal Cancers
NCT06864169Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of raludotatug deruxtecan in pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), colorectal adenocarcinoma and 3 more, sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 15 months. Started Apr 2025; status: active, not recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)colorectal adenocarcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06864169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864169.